Khalaf Daniel, Hilton John F, Clemons Mark, Azoulay Laurent, Yin Hui, Vandermeer Lisa, Dent Susan, Hopkins Sean, Bouganim Nathaniel
Division of Hematology-Oncology, University of Montreal - Notre-Dame Hospital, Montreal, QC H2L 4M1, Canada ; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
Oncol Lett. 2014 Mar;7(3):866-870. doi: 10.3892/ol.2014.1782. Epub 2014 Jan 7.
Platinum-based chemotherapy regimens are frequently used in patients with triple-negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum-based chemotherapy is associated with an increased time to progression when compared with non-platinum-based regimens in TNBC and non-TNBC. A retrospective analysis was conducted within a cohort of patients with metastatic breast cancer who received platinum-based chemotherapy at a single institution. Data were collected for up to three lines of treatment for metastatic disease. Time to progression was determined for platinum-based chemotherapy and non-platinum-based regimens for each line of treatment. Adjusted hazard ratios (HRs), together with 95% confidence intervals (CIs) were estimated comparing the time to progression associated with the use of platinum-based chemotherapy versus non-platinum-based regimens. A total of 159 patients were included in the analysis, with 58 diagnosed with TNBC. Among the patients with TNBC, compared with non-platinum-based chemotherapy, no correlation was identified between platinum-based chemotherapy and an improved time to progression [first line: HR, 0.97 (95% CI, 0.40-2.35); second line: HR, 0.91 (95% CI, 0.42-2.01); and third line: HR, 2.83 (95% CI, 0.73-11.03)]. By contrast, patients with non-TNBC appeared to improve with non-platinum-based chemotherapy [first line: HR, 2.57 (95% CI, 1.11-5.99); second line: HR, 1.91 (95% CI, 1.00-3.63); and third line: HR, 1.08 (95% CI, 0.53-2.18)]. Although the present study was limited by the sample size and its observational nature, the results indicated that platinum-based chemotherapy does not offer a discernible or distinct advantage compared with standard regimens in patients with TNBC, and is perhaps less efficacious in patients with non-TNBC.
铂类化疗方案常用于三阴性乳腺癌（TNBC）患者。本研究的目的是评估与非铂类方案相比，铂类化疗是否会使TNBC和非TNBC患者的疾病进展时间延长。对在单一机构接受铂类化疗的转移性乳腺癌患者队列进行了回顾性分析。收集了转移性疾病多达三线治疗的数据。确定了每线治疗中铂类化疗和非铂类方案的疾病进展时间。估计了调整后的风险比（HRs）以及95%置信区间（CIs），以比较使用铂类化疗与非铂类方案相关的疾病进展时间。共有159名患者纳入分析，其中58名被诊断为TNBC。在TNBC患者中，与非铂类化疗相比，未发现铂类化疗与改善疾病进展时间之间存在相关性[一线：HR，0.97（95%CI，0.40 - 2.35）；二线：HR，0.91（95%CI，0.42 - 2.01）；三线：HR，2.83（95%CI，0.73 - 11.03）]。相比之下，非TNBC患者似乎在接受非铂类化疗后病情有所改善[一线：HR，2.57（95%CI，1.11 - 5.99）；二线：HR，1.91（95%CI，1.00 - 3.63）；三线：HR，1.08（95%CI，0.53 - 2.18）]。尽管本研究受样本量及其观察性研究性质的限制，但结果表明，与标准方案相比，铂类化疗在TNBC患者中并未显示出明显优势，在非TNBC患者中可能疗效较差。
